Lymphohistiocytoid mesothelioma is a rare subtype of asbestos cancer that makes up less than 1 percent of all asbestos-related cancer cases. Tumors are made up of a dense bundle of inflammatory immune cells, including lymphocytes (a type of white blood cell), plasma cells and immobile immune cells called histiocytes. Also called macrophages, histiocytes ingest foreign substances to protect the body from infection.
Written by Karen Selby, RN Edited By Walter Pacheco Medically Reviewed By Dr. Rupesh Kotecha
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Selby, K. (2023, February 22). Lymphohistiocytoid Mesothelioma. Asbestos.com. Retrieved June 8, 2023, from https://www.asbestos.com/mesothelioma/lymphohistiocytoid/
Selby, Karen. "Lymphohistiocytoid Mesothelioma." Asbestos.com, 22 Feb 2023, https://www.asbestos.com/mesothelioma/lymphohistiocytoid/.
Selby, Karen. "Lymphohistiocytoid Mesothelioma." Asbestos.com. Last modified February 22, 2023. https://www.asbestos.com/mesothelioma/lymphohistiocytoid/.
What Lymphohistiocytoid Mesothelioma?
Lymphohistoicytoid mesothelioma is an aggressive sarcomatoid cell type. These tumors tend to have a mix of epithelioid cells and inflammatory cells. Some patients with this subtype may have an optimistic prognosis, like an epithelial cell diagnosis.
There are few reported cases of this subtype. Doctors often misdiagnose it as another condition, often non-Hodgkin’s lymphoma. Symptoms and treatment options mirror those of other pleural mesothelioma types. Its rarity leaves researchers few opportunities to study it, and there is little information for review. Pathologists have identified specific tumor characteristics that can aid in an accurate diagnosis.
Quick Facts About Lymphohistiocytoid Mesothelioma
- First discovered in 1988
- Characterized by dense bundles of inflammatory and immune cells
- Sarcomatoid cell type, mixed with some epithelioid
- May be misdiagnosed as lymphoma
- Treated with surgery, chemotherapy and radiation therapy
Diagnosing Lymphohistiocytoid Mesothelioma
First, surgeons take a sample of the tumor during a biopsy. Then, they send it to a lab for a pathological study. Many of the immune cells found in this subtype mimic other cancers. This can lead to misdiagnosis.
Common differential diagnoses of lymphohistiocytoid mesothelioma
- Non-Hodgkin’s lymphoma
- Hodgkin’s lymphoma
- Lymphoepithelial carcinoma
- Sarcomatoid carcinoma of the lung
- Pleural-based thymic epithelial tumor
Under a microscope, histological studies reveal large, atypical polygonal to spindle-shaped histiocytoid cells. Mixed with these cells are white blood cells.
Other signs of this tumor type are:
- Diffuse pleural thickening
- Small nodules throughout the pleura (the lining of the lung)
- Pleural effusion (a fluid buildup between pleural layers)
In this type of mesothelioma, histological studies and visual presentation of pleural-tissue changes are not usually enough to make a firm diagnosis. For a definitive diagnosis of lymphohistiocytoid mesothelioma, an immunohistochemical panel of antibodies for pathological staining is mandatory so that tumors can be differentiated from others that are similar.
In immunohistochemistry, pathologists add antibodies to tumor tissue. These stain the tissue when there is a positive reaction. Each cancer has certain positive markers. Seeing them under a microscope can help make a more accurate diagnosis.
To prepare a sample, the pathologist fixes tumor tissue in a paraffin block. They then trim the block into thin slices and mount them on a slide. In studies, these tumor cells expressed cytokeratin, vimentin, calretinin and CH5/6. They were negative for lymphoid and macrophage markers. AE1/AE3 and calretinin antibodies are the most reliable for staining tissue samples.
Symptoms, Treatment and Prognosis of Lymphohistiocytoid Mesothelioma
Symptoms are like other types of pleural mesothelioma. They may include:
- Chest pain
- Weight loss
Treatment information is limited for this type. Patients generally receive surgery, chemotherapy and radiation therapy.
Treatments for Lymphohistiocytoid Mesothelioma
- Radiation therapy
Early cases in a 1988 report showed no positive response to chemotherapy or radiation. The three patients in the report survived between four and eight months. A 2007 study evaluated 22 cases. This study showed improvement and a positive response to treatment. Patients had extended life spans. Their survival ranged between 32 and 40 months after diagnosis.
One encouraging case study showed a spontaneous regression of the tumor. Doctors removed tumors from the patient via surgery. The patients remained alive and without symptoms for 12 years after the initial presentation. In a small number of studies, some patients survived as much as six years after diagnosis. Doctors suggest that immune cells in this tumor may contribute to spontaneous regression.